Promacta (eltrombopag olamine)

Manufacturer:

Novartis

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Manufacturer Website

phone:

Enrollment Forms:

Synergen Prescription Form

Patient Support Form

Approved Indication:

treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic imune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy and whose degree of thrombocytopenia and clinical condition increases the risk for bleeding
treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy when the degree of thrombocytopenia prevents the ability to initiate or maintain interferon-based therapy
in combination with standard immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia
treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy

Conditions:

Thrombocytopenia
Aplastic Anemia

Therapeutic Area:

Hepatology
Oncology